The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase
1990

Inhibition of Cellular Recovery in Human Tumor Cells by Topoisomerase Inhibitors

publication Evidence: moderate

Author Information

Author(s): S.R.R. Musk, G.G. Steel

Primary Institution: Radiotherapy Research Unit, Institute of Cancer Research

Hypothesis

Topoisomerase I plays a role in the repair of DNA damage induced by ionizing radiation, while topoisomerase II does not.

Conclusion

Camptothecin significantly affects cell survival following both high and low dose-rate irradiation, while VP16 does not.

Supporting Evidence

  • Camptothecin sensitized cells to radiation at high dose rates with a dose enhancement ratio of 1.10.
  • At low dose rates, camptothecin completely abolished the sparing effect with a dose enhancement ratio of 1.32.
  • VP16 had no effect on the survival curves even at highly cytotoxic doses.

Takeaway

This study found that a drug called camptothecin helps stop cancer cells from fixing damage caused by radiation, but another drug, VP16, doesn't help at all.

Methodology

Human bladder carcinoma cell line RT112 was irradiated at high and low dose rates and exposed to camptothecin and VP16 to assess their effects on cell survival and DNA repair.

Limitations

The study does not conclusively establish the involvement of topoisomerases in the repair process due to the use of inhibitors that may have broader effects.

Participant Demographics

Human bladder carcinoma cell line RT112.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication